Clinically, long-term treatment with ibrutinib, an inhibitor that forms irreversible covalent bonds to BTK, reversed CD8 T cell exhaustion and protected T cells from proliferation-induced senescence in chronic lymphocytic leukemia (B-CLL) patients. This evidence concerns the gene CD8A and B-cell chronic lymphocytic leukemia.